Ameloblastoma is a slow-growing neoplasm of the jaw, for which the standard treatment is surgical removal of the lesion with high recurrence rates and elevated morbidity. Systemic therapy is not established in the literature.
We present a case of a 29-year-old woman diagnosed with an ameloblastoma of the left mandible who had been subjected to several surgical procedures over twenty years due to multiple local recurrences. Molecular testing revealed a BRAF V600E mutation, and vemurafenib was started. She experienced complete resolution of symptoms related to the disease, and image scans evidenced continuous shrinkage of the neoplastic lesion after eleven months of therapy.
This is the first report showing clinical benefit and radiological response with vemrafenib for recurrent ameloblastoma. Targeted therapy addressing BRAF V600E mutation has the potential to change clinical practice of this rare disease.
Mendenhall WM, Werning JW, Fernandes R, Malyapa RS, Mendenhall N. Ameloblastoma. Am J ClinOncol. 2007;30:645–8. CrossRef
Diniz MG, Gomes CC, Guimarães BVA, Castro WH, Lacerda JCT, Cardoso SV. Assessment of BRAF-V600E and SMOF412E mutations in epithelial odontogenic tumours. Tumor Biol. 2015;36:5649–53. CrossRef
Faden DL, Algazi A. Durable treatment of ameloblastoma with single agent BRAFi re: clinical and radiographic response with combined BRAF targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst. 2016;109:pii:djw190. Print 2017 Jan CrossRef
Dassule HR, Lewis P, Bei M, Maas R, AP MM. Sonic heedgehog regulates growth and morphogenesis of the tooth. Development. 2000;127(22):4775–85. PubMed
Woodroffe RW, Abel TJ, Fletcher A, Grossbach A, Van Daele DJ, O'Brien E, Greenlee JD. Endoscopic transnasal resection of ameloblastoma with intracranial extension. J ClinNeurosci. 2014;21:855–9.
- Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation
Gustavo S. Fernandes
Daniel M. Girardi
João Paulo G. Bernardes
Felipe P. Fonseca
Eduardo R. Fregnani
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II